PUNE, India, January 5, 2017 /PRNewswire/ --
According to a new market research report "Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO) & Application (Oncology, Blood Disorders) - Global Forecast to 2021" published by MarketsandMarkets, The global market is expected to reach USD 10.90 Billion by 2021 from USD 3.39 Billion in 2016, at a CAGR of 26.3% during the forecast period.
Browse 91 market data Tables and 42 Figures spread through 152 Pages and in-depth TOC on "Biosimilars Market"
Early buyers will receive 10% customization on this report.
The report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Biosimilars Market along with the estimates and forecasts of the revenue and market share analysis. The major factors driving the growth of this market are the increasing demand for biosimilar drugs due to their cost-effectiveness, growing pressure to curtail healthcare expenditure, rising geriatric population, strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars, and increasing government support and initiatives to develop and promote biosimilars.
Inquiry Details: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=40
This report segments the market on the basis of product, manufacturing type, application, and region. On the basis of product, the Biosimilars Market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. In 2016, the recombinant non-glycosylated proteins segment is expected to account for the largest share of the market. New product launches, cost-effectiveness, growing incidence of diabetes, and presence of many biosimilar versions of insulin in the pipeline are the factors driving the growth of this segment.
Based on manufacturing type, the Biosimilars Market is segmented into in-house manufacturing and contract manufacturing organizations. In 2016, the contract manufacturing segment is expected to account for the largest share of the market.
Based on application, the Biosimilars Market is segmented into oncology, blood disorders, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. The oncology segment is expected to grow at the highest CAGR during the forecast period. The rising incidence of cancer, high cost of biologics, pressure to reduce healthcare expenditure, and low cost of biosimilars are factors contributing to the growth of this segment.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=40
Based on region, the global Biosimilars Market is segmented into North America, Europe, Asia, and RoW. Asia is expected to grow at the highest CAGR during the forecast period. This can be attributed to factors such as the low per capita consumption, rapid growth in economies, rise in technological innovation, trade links, and the rise in medical tourism.
The key players in the Biosimilars Market include Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Biocon Ltd. (India), Dr. Reddy's Laboratories (India), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion Inc. (South Korea), and Samsung Bioepis (South Korea).
Browse Related Reports:
Antibody Production Market by Product (Equipment, Consumables), Type (Monoclonal, Polyclonal), Technology (Hybridoma) & by End-User (Biopharmaceutical Companies, Diagnostic Labs, Research Institutes) - Analysis & Global Forecast to 2019
Protein Engineering Market by Technology (Rational Protein Design, Irrational Protein Design), Product (Instrument, Services), Protein Type (Monoclonal Antibodies, Interferon, Growth Hormone), End User (Academics Institutes, CROs) - Global Forecast to 2020
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets